CL2024000785A1 - Moléculas de unión a d3 y usos de estas - Google Patents

Moléculas de unión a d3 y usos de estas

Info

Publication number
CL2024000785A1
CL2024000785A1 CL2024000785A CL2024000785A CL2024000785A1 CL 2024000785 A1 CL2024000785 A1 CL 2024000785A1 CL 2024000785 A CL2024000785 A CL 2024000785A CL 2024000785 A CL2024000785 A CL 2024000785A CL 2024000785 A1 CL2024000785 A1 CL 2024000785A1
Authority
CL
Chile
Prior art keywords
binding molecules
antibodies
including anti
molecules
binding
Prior art date
Application number
CL2024000785A
Other languages
English (en)
Inventor
Chen Yunying
Cheng Yongqing
Wang Xia
Gu Jijie
Original Assignee
Wuxi Biologics Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wuxi Biologics Ireland Ltd filed Critical Wuxi Biologics Ireland Ltd
Publication of CL2024000785A1 publication Critical patent/CL2024000785A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Prostheses (AREA)
  • Steroid Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

En la presente divulgación se proporcionan moléculas de unión a D3, incluidos anticuerpos anti-D3, y sus usos.
CL2024000785A 2021-09-17 2024-03-15 Moléculas de unión a d3 y usos de estas CL2024000785A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2021119011 2021-09-17

Publications (1)

Publication Number Publication Date
CL2024000785A1 true CL2024000785A1 (es) 2024-08-09

Family

ID=85602107

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2024000785A CL2024000785A1 (es) 2021-09-17 2024-03-15 Moléculas de unión a d3 y usos de estas

Country Status (15)

Country Link
EP (1) EP4401775A1 (es)
JP (1) JP2024535851A (es)
KR (1) KR20240055852A (es)
CN (1) CN118234510A (es)
AU (1) AU2022345323A1 (es)
CA (1) CA3231586A1 (es)
CL (1) CL2024000785A1 (es)
CO (1) CO2024003144A2 (es)
CR (1) CR20240135A (es)
DO (1) DOP2024000052A (es)
EC (1) ECSP24021498A (es)
IL (1) IL311510A (es)
MX (1) MX2024003331A (es)
PE (1) PE20241133A1 (es)
WO (1) WO2023041041A1 (es)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2530091T (pt) * 2010-01-29 2018-05-17 Chugai Pharmaceutical Co Ltd Anticorpo anti-dll3
GB201302447D0 (en) * 2013-02-12 2013-03-27 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
BR112016004073A8 (pt) * 2013-08-28 2018-06-12 Stemcentrx Inc Anticorpos criados por engenharia, conjugados de anticorpo fármaco, seu método de preparação e seu uso, composição farmacêutica e seu uso, kits, e métodos para administrar uma pirrolobenzodiazepina (pbd) a uma célula de câncer que expressa dll3 e para determinar a citotoxicidade de um conjugado de anticorpo fármaco anti-dll3
EP3107576A4 (en) * 2014-02-21 2017-09-06 Abbvie Stemcentrx LLC Anti-dll3 antibodies and drug conjugates for use in melanoma
TW202346349A (zh) * 2015-07-31 2023-12-01 德商安美基研究（慕尼黑）公司 Dll3及cd3抗體構築體
JP2018529656A (ja) * 2015-08-20 2018-10-11 アッヴィ・ステムセントルクス・エル・エル・シー 抗ｄｌｌ３抗体薬物コンジュゲートおよび使用方法
US20190225685A1 (en) * 2018-01-24 2019-07-25 Abbvie Stemcentrx Llc Anti-dll3 antibody drug conjugates and methods of use
CN118146372A (zh) * 2018-05-08 2024-06-07 凡恩世制药(北京)有限公司 抗dll3抗体及其用途

Also Published As

Publication number Publication date
AU2022345323A1 (en) 2024-03-28
ECSP24021498A (es) 2024-06-28
KR20240055852A (ko) 2024-04-29
CR20240135A (es) 2024-05-17
WO2023041041A1 (en) 2023-03-23
EP4401775A1 (en) 2024-07-24
IL311510A (en) 2024-05-01
MX2024003331A (es) 2024-06-19
CA3231586A1 (en) 2023-03-23
PE20241133A1 (es) 2024-05-24
JP2024535851A (ja) 2024-10-02
DOP2024000052A (es) 2024-06-16
CN118234510A (zh) 2024-06-21
CO2024003144A2 (es) 2024-05-30

Similar Documents

Publication Publication Date Title
DOP2020000236A (es) Anticuerpos il-1 1ra
CL2017000954A1 (es) Moléculas de unión a antígeno biespecificas activadoras de células t
DOP2020000245A (es) Anticuerpos il-11
MA49034B1 (fr) Anticorps anti-lag3
CY1124108T1 (el) Μορια συνδεσης που αναστελουν την αναπτυξη καρκινου
PH12020500398A1 (en) Antibody-pyrrolobenzodiazepine derivative conjugate
CO2018010855A2 (es) Nuevos anticuerpos anti-sirpa y sus aplicaciones terapéuticas
AR109771A1 (es) Moléculas biespecíficas de unión a antígeno activadoras de células t
CL2019002542A1 (es) Nuevas moléculas de unión a antígeno biespecíficas capaces de unirse específicamente a cd40 y a fap.
CR20180162A (es) Moléculas biespecíficas de unión a antígeno activadoras de células t
CO6362016A2 (es) Polipeptidos de eritropoyetina animal modificados y sus usos
CL2019002626A1 (es) Anticuerpos anti-par2 y usos de los mismos.
BR112017023761A2 (pt) composições e métodos para a produção biológica de metionina
NI202000087A (es) Anticuerpos ant-tmeff2 monoespecíficos y multiespecíficos y sus usos
CL2021003241S1 (es) Automóvil.
UY4891S (es) Calzado
CL2019002831A1 (es) Dispositivos y sistemas de difusión microfluídica, y métodos de fabricación y uso
ECSP24021498A (es) Moléculas de unión a d3 y usos de estas
CO2023010689A2 (es) Anticuerpos y usos de estos
CL2021002289S1 (es) Automóvil.
PE20210466A1 (es) ANTICUERPO MONOCLONAL ANTI-IL-5Ralfa
CL2023002749S1 (es) Dispositivo de electroporación.
MA53052A1 (es)
AR121333A1 (es) Moléculas de unión biespecíficas
CO2024007117A2 (es) Proteínas de unión que reconocen al antígeno hpv16 e7 y usos de las mismas